Scarica l'app Stockscreener
26.77
1.37%
-0.375
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$27.14
Aprire:
$26.42
Volume 24 ore:
3.37M
Relative Volume:
0.34
Capitalizzazione di mercato:
$10.41B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.0659
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-0.23%
1M Prestazione:
+7.08%
6M Prestazione:
+8.31%
1 anno Prestazione:
-51.17%
Intervallo 1D:
$26.24
$26.94
Intervallo di 1 settimana:
$26.01
$28.48
Portata 52W:
$23.15
$57.69
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
26.76 | 10.60B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.48 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
486.06 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.06 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
840.69 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.31 | 34.93B | 4.56B | -176.77M | 225.30M | -1.7177 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna to Present Promising Phase 1/2 Clinical and Safety Data for Cancer Antigen Therapy mRNA-4359 at ESMO 2025 - Insider Monkey
Q3 Earnings Estimate for Moderna Issued By Leerink Partnrs - MarketBeat
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - Monroe Evening News
Moderna Inc. Stock Advances 5.5%, Outperforms Peers - 富途牛牛
How Moderna Inc. (MRNA) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Why Moderna Might Be a One-Hit Wonder - The Globe and Mail
Why Moderna Might Be a One-Hit Wonder - The Motley Fool
Intraday pattern recognizer results for Moderna Inc.Quarterly Trade Summary & Step-by-Step Trade Execution Guides - newser.com
Leerink Partners Adjusts Price Target on Moderna to $16 From $15, Maintains Underperform Rating - MarketScreener
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 - The Marion Star
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note - sharewise.com
Moderna: Q3 Earnings PreviewI Fear A Halloween Horror Show (Downgrade) (NASDAQ:MRNA) - Seeking Alpha
Lobbying Update: $80,000 of MODERNA US INC. lobbying was just disclosed - Quiver Quantitative
Moderna (MRNA) Tops List of Most Shorted S&P 500 Stocks - GuruFocus
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - Norwich Bulletin
How to use Fibonacci retracement on Moderna Inc.July 2025 Spike Watch & Low Volatility Stock Recommendations - newser.com
Key facts: Moderna faces cash flow challenges; stock rises on therapy data - TradingView
Moderna (MRNA) Stock Trades Up, Here Is Why - The Globe and Mail
Moderna’s Off-The-Shelf Cancer Immunotherapy Shows Early Promise - insights.citeline.com
Is Moderna Inc. meeting your algorithmic filter criteriaRate Hike & Fast Exit Strategy with Risk Control - newser.com
Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients - Benzinga
Moderna (MRNA) Unveils Promising Data on mRNA-4359 for Melanoma Treatment - GuruFocus
What’s next for Moderna Inc. stock priceJuly 2025 Highlights & Consistent Growth Stock Picks - newser.com
Moderna (MRNA) Tops Healthcare Short Interest Rankings - GuruFocus
Respiratory Syncytial Virus (RSV) Market Explosion To hit - openPR.com
Moderna Claims Early Victory for Cancer Antigen in Melanoma - BioSpace
Moderna, Inc. (MRNA) Stock Analysis: Navigating Volatility With A 65% Potential Upside - DirectorsTalk Interviews
Moderna reports early cancer therapy data at medical conference - StreetInsider
KLP Kapitalforvaltning AS Sells 34,400 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Janney Montgomery Scott LLC - MarketBeat
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress - Times Herald
Moderna says it presents promising early data for investigational cancer antigen therapy - MarketScreener
67% ORR in PD-L1+ tumors — Moderna's mRNA-4359 shows 24% overall ORR in CPI‑R/R melanoma at ESMO - Stock Titan
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans - Shreveport Times
Moderna (NASDAQ:MRNA) Given New $32.00 Price Target at Morgan Stanley - MarketBeat
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know - Yahoo Finance
MRNA: Morgan Stanley Raises Price Target for Moderna | MRNA Stoc - GuruFocus
Covid-19 Vaccine Recommendations | Moderna - OurQuadCities
Moderna assists with the evolving landscape of COVID-19 vaccine - KHGI
AstraZeneca ups investment in Virginia; Moderna vets launch VC fund - BioPharma Dive
Moderna (NASDAQ:MRNA) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - Newport Daily News
Should Moderna's (MRNA) Improved Revenue Trends Prompt New Action From Investors? - Yahoo Finance
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.68%
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):